Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Code:
NCT07940738
Conditions
Hematologic Malignancy
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Efineptakin Alfa (rhIL-7-hyFc)
Brief summary:
Conditions
Hematologic Malignancy
Study ID
NCT07940738
Start date
Dec, 2026
Status verified date
Nov, 2026
Completion date
Jun, 2028
Anticipated
Primary completion date
Jun, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
12 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Efineptakin Alfa (rhIL-7-hyFc)
Interventions
Efineptakin Alfa (rhIL-7-hyFc)
Primary outcome measure
Central contacts
Locations
Moffitt Cancer Center
Recruiting
Tampa, Florida, United States, 33612
Principal Investigator:
Sayeef Mirza, MD
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Last update posted
Nov 17, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.